Can I Take Turmeric / Curcumin with Repatha (Evolocumab)?

How Evolocumab Works and Why Its Metabolism Matters

Evolocumab is a fully human IgG2 monoclonal antibody that binds and inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), the protein that degrades LDL receptors on hepatocytes [1]. By blocking PCSK9, Repatha allows more LDL receptors to recycle to the hepatocyte surface, dramatically lowering circulating LDL-C.

Proteolytic Clearance, Not Liver Enzymes

Unlike small-molecule statins, evolocumab is not metabolized by cytochrome P450 (CYP) enzymes. It is cleared through two pathways: target-mediated disposition (binding to circulating PCSK9) and nonspecific proteolytic degradation by the reticuloendothelial system [2]. This means any herb or supplement that modulates CYP3A4, CYP2C9, or P-glycoprotein will not meaningfully change evolocumab blood levels.

What the FOURIER Trial Established

The phase 3 FOURIER trial (N=27,564) demonstrated that evolocumab added to statin therapy reduced LDL-C by a mean of 59% and cut the composite of cardiovascular death, myocardial infarction, or stroke by 15% over a median 2.2 years (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001) [3]. Maintaining that LDL reduction without pharmacokinetic disruption from supplements is therefore clinically meaningful.

What Turmeric and Curcumin Do in the Body

Turmeric (Curcuma longa) contains roughly 2 to 5% curcuminoids by dry weight, of which curcumin is the most studied [4]. Bioavailability of plain curcumin powder is low, often below 1%, but formulations with piperine (black pepper extract), phospholipid complexes, or nanoparticles can increase absorption 20-fold or more [5].

Anti-Inflammatory Pathways

Curcumin down-regulates NF-kB signaling, inhibits COX-2 and LOX enzymes, and reduces circulating IL-6 and TNF-alpha [4]. These effects are why many patients with osteoarthritis or general inflammation reach for it.

Antiplatelet and Mild Anticoagulant Activity

This is the relevant concern for Repatha users. Curcumin inhibits platelet aggregation by suppressing thromboxane B2 synthesis and reducing ADP-induced aggregation [6]. A 2012 in-vitro study found concentration-dependent inhibition of collagen-induced platelet activation [6]. Oral doses above roughly 4 g/day in human subjects have been associated with measurable prolongation of bleeding time in small studies, though evidence from large randomized trials is limited.

Curcumin also has mild effects on coagulation factors at high doses. One 2019 review in the journal Nutrients noted that high-dose curcumin supplementation "may enhance the anticoagulant effect of drugs that affect platelet function," naming NSAIDs and antiplatelet agents specifically [7].

Independent LDL-Lowering Effects

A 2017 meta-analysis of 7 randomized controlled trials (N=649) found curcumin supplementation reduced LDL-C by a mean of 12.26 mg/dL (95% CI: 6.59 to 17.93 mg/dL) compared to placebo [8]. For a patient already on evolocumab with LDL-C near goal, this additive effect is generally favorable but should be tracked to avoid over-treatment in the rare patient on multiple lipid-lowering agents.

The Actual Interaction: Pharmacodynamic, Not Pharmacokinetic

The phrase "drug-supplement interaction" often implies one substance changes the blood level of the other. That pathway does not apply here.

Why CYP450 Arguments Do Not Apply to Repatha

Curcumin is a moderate inhibitor of CYP3A4 and CYP2C9 in vitro [9]. For a statin like atorvastatin (a CYP3A4 substrate), this could theoretically raise statin plasma concentrations. Evolocumab is not a CYP substrate. Its clearance is entirely enzymatic via peptide bond hydrolysis. Published pharmacokinetic modeling for IgG-class biologics confirms that polyphenols and CYP modulators do not alter monoclonal antibody exposure [2].

The Pharmacodynamic Overlap That Does Matter

Both evolocumab's patient population and curcumin users overlap heavily with people who also take aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor) for established ASCVD. Adding curcumin's antiplatelet activity on top of antiplatelet therapy plus anticoagulants creates a multi-layer bleeding risk that is not captured in any single pairwise interaction study [10].

A practical way to think about bleeding risk stratification in this population:

• Low risk: Culinary turmeric only (under 1.5 g/day), no antiplatelet drugs, no anticoagulants.
• Moderate risk: Curcumin supplement 500 to 2,000 mg/day plus low-dose aspirin 81 mg.
• Higher risk: Curcumin supplement above 2,000 mg/day, or any concentrated extract with piperine, combined with dual antiplatelet therapy or a direct oral anticoagulant (DOAC).

The evolocumab injection itself does not add to bleeding risk. The risk comes from the patient's full medication and supplement stack.

Dose-Dependent Considerations for Curcumin

Dose matters more than the simple yes/no of whether to combine these two substances.

Culinary Amounts

A teaspoon of ground turmeric weighs roughly 3 grams and contains about 60 to 100 mg of curcumin. Using turmeric in food at this level presents a negligible antiplatelet concern [4]. Patients on Repatha who cook with turmeric daily are very unlikely to encounter any clinically meaningful interaction.

Standard Supplement Capsules

Most commercial curcumin supplements provide 500 to 1,000 mg per capsule, with instructions for one to three capsules daily. At 500 to 1,000 mg/day without a bioavailability enhancer, absorption remains poor and systemic curcumin exposure is low [5]. This range is generally considered low-risk alongside evolocumab, though physicians should still be informed.

High-Dose or Enhanced Formulations

Products labeled "BCM-95," "Meriva," "Theracurmin," or any curcumin plus piperine combination achieve substantially higher plasma concentrations [5]. At doses above 4 g/day of these enhanced formulations, the antiplatelet signal becomes more clinically relevant, particularly for patients on aspirin or any anticoagulant [7]. The FDA has listed turmeric/curcumin as GRAS (generally recognized as safe) for food use, but GRAS status does not extend to high-dose therapeutic supplements [11].

What Monitoring Looks Like in Practice

Patients already taking both evolocumab and curcumin supplements do not need to panic. The combination does not appear in FDA adverse event databases as a documented serious interaction. Still, periodic monitoring makes clinical sense.

Signs to Watch For

Patients should notify their prescriber if they notice any of the following:

• Bruising that appears without clear injury
• Bleeding gums when brushing teeth
• Cuts that take more than 10 minutes to stop bleeding
• Blood in urine or stools

These signs are not specific to this combination but serve as a general alert in any patient on agents with antiplatelet activity.

Lab Monitoring

There is no validated blood test for "curcumin antiplatelet effect" in routine practice. For patients on concurrent anticoagulation, INR (if on warfarin) should be checked within four to six weeks of starting or stopping any curcumin supplement above 1,000 mg/day [7]. Evolocumab itself does not affect INR.

LDL-C panels are already standard for Repatha patients every three to twelve months depending on the prescribing guideline [12]. A lipid panel will incidentally capture any additive LDL-lowering from curcumin, allowing dose adjustments to co-prescribed statins if LDL-C falls below the treatment target.

Guidelines on Supplement Disclosure

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states that clinicians should "routinely inquire about use of dietary supplements, herbal products, and over-the-counter medications in all patients receiving lipid-lowering pharmacotherapy" [12]. Patients frequently omit supplement details from medication lists, and the clinical burden of asking falls on the provider at each visit.

Evidence Summary: What the Research Actually Shows

No dedicated randomized controlled trial has examined the evolocumab-plus-curcumin combination directly. The interaction assessment is therefore built from mechanism-based reasoning plus trials on curcumin's individual effects.

Curcumin Lipid Trials

Beyond the 2017 LDL meta-analysis cited above, a 2019 systematic review published in Nutrition Journal (N=1,356 across 13 RCTs) found curcumin reduced total cholesterol by 15.65 mg/dL and triglycerides by 28.33 mg/dL, with LDL reduction consistent across subgroups [13]. These effects appear additive rather than synergistic with PCSK9 inhibition, as they operate through separate pathways: curcumin appears to up-regulate LDL receptor expression independently of PCSK9 in some cell-line studies [13].

Curcumin Antiplatelet Trials

A small but carefully designed crossover study (N=18) published in the American Journal of Clinical Nutrition found that 4 g/day of curcumin for 4 weeks significantly reduced ex-vivo platelet aggregation induced by collagen (P<0.05) without changing PT or aPTT [6]. The authors concluded the effect was clinically modest at this dose but "warrants caution in patients receiving concurrent antiplatelet therapy."

Evolocumab Safety Data

The FOURIER open-label extension followed patients for up to 8.4 years and reported no increase in serious hemorrhagic events compared to placebo [14]. This establishes that evolocumab alone does not meaningfully raise bleeding risk, which means any bleeding concern in the combination scenario comes entirely from curcumin and co-prescribed antiplatelet drugs.

Practical Advice for Patients Currently Taking Both

If you are already taking Repatha and a curcumin supplement and have not mentioned it to your cardiologist or internist, bring it up at your next appointment. No emergency action is required for most patients.

Steps to Take Before Your Next Appointment

Write down the exact product name, the curcumin dose per serving, how many servings you take per day, and whether the formula contains piperine or a bioavailability enhancer. This information lets your prescriber assess your actual systemic exposure rather than relying on a generic "I take turmeric" disclosure.

If You Are Also on Aspirin or a Blood Thinner

Tell your prescriber as soon as possible, particularly if you are on dual antiplatelet therapy after a recent coronary stent or on a DOAC such as rivaroxaban or apixaban. Your prescriber may ask you to reduce curcumin to a culinary dose only, or may decide the current combination is acceptable based on your full cardiovascular risk profile.

If You Want to Start a Curcumin Supplement

Ask your prescriber before starting. For most stable Repatha patients on aspirin monotherapy, a standard 500 mg/day unenhanced curcumin capsule is unlikely to create a clinically significant problem. Initiating above 2,000 mg/day of an enhanced formulation without physician sign-off is not advisable.